Haemonetics announces $525M convertible senior notes offering due 2029

HAEMONETICS CORP

$525M principal amount of convertible senior notes due 2029, with option for additional $75M.
Notes accrue interest semi-annually, mature June 1, 2029; settlement in cash up to $1,000 principal, then stock/cash.
Proceeds to fund capped call transactions to offset dilution, plus working capital and general corporate purposes.
Offering only to qualified institutional buyers under Rule 144A; notes not registered under Securities Act.
Option counterparties may enter derivative transactions affecting HAE stock price around pricing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.